After the phase I study, where scientists found a reduced cell count in 60 per cent patients, they launched their phase II clinical trial in an additional 36 patients.
Results from 41 patients who have completed the study show that 31 percent of patients had a 20 percent or greater sustained reduction in blood leukemia count, and 69 percent of patients with enlarged lymph nodes saw a reduction of node size of 50 percent or greater.
The researchers also studied the side effects, since EGCG was being studied in patients who did not otherwise need treatment.
"All in all, the treatment was well tolerated with very mild side effects in most patients," Shanafelt says.
Kay however warns that not all CLL patients can use the treatment without consulting their oncologists and proper lab tests.
The findings are to be presented Monday, June 7, during the annual meeting of the American Society of Clinical Oncology (ASCO).
Source-ANI